Subscribe to our Newsletters !!
The connection between genes and traits is one of
Our customers depend on the high performance and r
Few names in the medical history have had a profou
Alembic Pharmaceuticals Limited appoints Mr. Manis
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Mumbai, 9th August 2021: Merck Specialties Pvt ltd, the healthcare business of Merck in India, today launched Pergoveris® Pen for advanced infertility treatment in India. This launch emphasizes the company’s motive of fulfilling unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency.
• Pergoveris® Pen is the first-ever product with a combination of recombinant Follicle Stimulating Hormone and recombinant Luteinizing Hormone in a ready-to-use device to be used upon prescription by an IVF specialist • A globally approved pen filled by mass technology provides a safer self- administration fertility solution to infertile couples
Infertility is no less than an endemic for Indians and is vastly dependent on a proper ovulation cycle. Ovulation is a process whereby a mature, fertilizable oocyte is released from the ovarian follicle. This process is the result of a well-defined sequence of events that includes the combined effect of the pituitary gonadotropins, FSH, and LH. Any functional disorder of the hypothalamic-pituitary-ovarian axis may lead to the absence of or infrequent ovulation, resulting in infertility. The new Pergoveris® Pen allows an improved treatment experience for patients with severe FSH and LH deficiency upon prescription by an IVF specialist.
“As multiple studies suggest that nearly 27.5 million Indian couples deal with infertility and are actively seeking fertility solutions,1 we strive to fulfill dreams of such couples aspiring to become parents, by providing them with advanced treatment options. Our commitment to delivering an optimal range of products in the field of fertility medicines is a step forward with the latest addition of Pergoveris® ready-to-use Pen, being an only premixed combination of recombinant human FSH (rhFSH) and recombinant human LH (rhLH) in the Indian markets” said Anandram Narasimhan, Managing Director, Merck Specialities Pvt Ltd.”
The novel first-hand version of the Pergoveris® Pen is a breakthrough combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris® delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment. In addition, by eliminating the need for mixing, Pergoveris® Pen is the world’s first combined therapy option for recombinant gonadotropins, demonstrating the efficacy, safety, and combinability of recombinant follitropin alfa with recombinant lutropin alfa, in a single ready to inject device, using Filled-By-Mass Technology, for infertile women in a physiological ratio of 2:1.
*Refer to full prescribing information prior to use or use as directed by your IVF specialist only*
About Pergoveris® Pergoveris® is indicated for the stimulation of follicular development in adult women with severe LH and FSH deficiency. For more information on the product – Registered IVF specialists can refer to the Pergoveris® (Follitropin Alfa and Lutropin Alfa) Full Prescribing Information.
Warning: To be sold by retail on the prescription of a Gynaecologist only.
About Merck: Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Electronics. *For more information about Merck visit www.merckgroup.com. Reference: 1. Call for Action: Expanding IVF Treatment in India (E&Y Report July, 2015) For further information, please contact: Saritha Rajeev Hajare Email: [email protected]
Parichita Bhattacharjee Email: [email protected]
DISCLAIMER : This communication is for informative purposes only. It may refer to pharmaceutical products, diagnostic techniques, therapeutics or indications not yet registered or approved in a given country and it should be noted that, over time, currency and completeness of the data may change. For updated information, please contact the Company. This communication should not be used to diagnose, treat or prevent any disease or condition without the professional advice of a Registered Medical Practitioner, and does not replace medical advice or a thorough medical examination. Registered Medical Practitioners should use their independent professional judgement in checking the symptoms, diagnosing & suggesting the appropriate line of treatment for patients. Merck is not in any way influencing, propagating or inducing anyone to buy or use Merck products. Merck accepts no liability for any loss, damage or compensation claims in connection with any act or omission by anyone based on information contained in or derived through use of this communication.”
